samm levine

  • 01:06:40

    Episode 1: THE GODFATHER with Samm Levine

    · Sending The Wolfe

    SUBSCRIBE: iTunes | Google Play Music | Stitcher  Well, hot dog, here it is!Welcome to the first episode of my very own podcast, SENDING THE WOLFE. For those of you who don't know me, my name is Clarke Wolfe and I am an actress, an entertainment host, and a producer. For those of you who do know me, thank you for being here!First thing's first: I love movies. I always have. My earliest memories are of discovering some of my favorite films like THE WIZARD OF OZ, JAWS, and BACK TO THE FUTURE. Some of my most vivid memories are of the movies that rocked me in ways that I can never forget -- like watching THE EXORCIST for the first time at a Halloween night sleepover and not being able to sleep for a year, or laughing so hard I almost threw up during the "punch dancing" scene in HOT ROD (yes, I just mentioned HOT ROD in the same sentence as THE EXORCIST). I first got a subscription to Entertainment Weekly for Christmas when I was 12 years old. A few years later when I was in middle school, one of my rants was published in their reader letters section. Some of the closest bonds in my life were formed over watching and talking about movies, from learning about comedy with my dad while watching YOUNG FRANKENSTEIN and THE PRINCESS BRIDE, to solidifying some of my most dear and long lasting friendships quoting SOUTH PARK: BIGGER, LONGER, AND UNCUT, or experiencing magic for the first time watching LABYRINTH, THE NEVERENDING STORY, and BEETLEJUICE. Now, here I am, attempting to live out my dreams in Los Angeles, working in entertainment and bumping into some of my most beloved heroes, forming unlikely bonds, and still hoping to play a part in just a small slice of that Hollywood magic.With all of that being said, I believe that film and pop culture are an important window into people and a beautiful time capsule of humanity at a given time. Some iconic movies stand the test of time, and others, not so much. But by discussing cinema with a good friend, a respected colleague, or even a stranger, perhaps we can see things from a perspective that we didn't entertain before. And, at the end of the day, that is the point of this podcast: to connect to another human being through the powerful and the emotional language of cinema. Here's how this show works: my guest each week picks a movie off of any of the American Film Institute's 100 YEARS... lists and we talk about it. Then, at the end of the episode, the guest picks a film that is NOT on the list -- which is a surprise to me that is revealed as we record -- and we talk about it. And that's all, folks! The point of using the AFI lists as a starting point was honestly just to set up some simple boundaries as to what material we cover, and to explore, discover, and revisit some of the most acclaimed examples of American cinema. On the other hand, using the list is also to (hopefully) challenge the conventional wisdom of what classic and iconic American cinema can be. That's why I give the guests the chance to add their own pick to the list: because so often when it comes to deciding what is good, or iconic, or foundational, a lot of voices, experiences, and opinions are left out of the mix, and I wanted us to have a chance to weigh in. Which leads me to the final reason I wanted to start this podcast...For my entire professional career as a writer, a correspondent, an actress, or a host, I've been working for someone else. And that is great! I like having a job, and plan to continue to do that. But this podcast is all mine, which means that I am not limited to anyone's idea of who I am or what I can talk about. A lot of you may know me as a pundit who focuses mostly on horror movies and that is also great! I love and admire horror, science fiction, and fantasy probably more than other genres because I feel that genre storytelling can be, and often is, the most precise window into a culture at any given time. Genre often answers the incredibly difficult question: what are we afraid of right now? Some of those themes are universal and never go away (death, for example) and some of them are specific to the time and place (think popular American horror movies from 2005-2010 and the idea of the "torture porn" subgenre). And as much as I love and admire genre storytelling and will always be fascinated by it, my cinematic interests and influences range from Charlie Chaplin to MARY POPPINS to John Woo's FACE/ OFF to anything with Sandra Bullock in it and a lot of other things in between. I want to engage and examine those things too, and for now, SENDING THE WOLFE is how I'm going to do it.Now, our premiere episode, featuring the always affable and incredibly intelligent Samm Levine. Samm became my friend through -- you guessed it! -- movie trivia. And even though time-wise, I really haven't known him for that long, I feel like we've been friends forever. Samm and I have spent countless hours over lunches and dinners and other such things discussing and debating movies, telling stories, and usually challenging each other to analysis of our favorite films that we may not have thought of before. And that's why I wanted to have Samm on this show: because he is a wealth of knowledge, a passionate cinephile, and, of course, a total mensch. I hope you enjoy the premiere episode of SENDING THE WOLFE. If you would like to support the show, please visit the Patreon page where you can find all kinds of original content, including exclusive mini-episodes of STW, video newsletters, movie watch-a-longs, and lots more that are only available to active Patreon patrons. This show is a work in progress and may very well change and evolve over the course of its run, so if you have feedback, please feel free to head over to the CONTACT page and send me a message. Thank you again for joining me. And now, on with the show!xx, Clarke.CREDITS:Sound Engineer: Folsom Keller of DEEP FRYD DYNAMITE // Contact:"Sending The Wolfe" Theme: Sean KellerKey Art: Bryan E. WardBanner Art: Erik Wilson

  • 01:21:31

    Ep 350 - Rogue One - Samm Levine

    · Comedy Film Nerds

    *FILMS DISCUSSED: ROGUE ONE, COLLATERAL BEAUTY, LA LA LAND, DUNKIRK, BLADE RUNNER 2049* Graham and Chris welcome back Samm Levine into the CFN Santa workshop. Samm and Graham bury some hatchets. Chris and Graham liked Rogue One. Samm and Graham had to do a mini spoiler about how bad Collateral Beauty was. Chris had fun at LA LA Land. Dunkirk and Blade Runner 2049 trailers look great! Samm tells a Inglorious story. Ok DVDs and a bunch of business in theaters. This ep will make you want to sit on the aisles so you don't see the answers. 

  • 01:32:09

    Episode 091 - Samm Levine and Susan Burke

    · Probably Science

    Actor Samm Levine ( who made a name for himself on Freaks and Geeks and Inglourious Basterds and comedian Susan Burke ( who's received rave reviews for writing the film Smashed join Matt, Andy and Jesse this week to discuss: All-night comedy shows at UCB! Halloween robot costumes! Samm's Short Circuit 2 nostalgia! Samm playing doctor as a kid! Losing to Jon Hamm in the Leonard Maltin game! Monkeys who are hardwired to be scared of snakes! Hotel living! Jesse's fake Zagat binder for solo dining! The perks of priesthood! The secret to sneaking into things! Using levitating droplets of water to create nanoparticles! Samm's gold-collecting dentist father! Using teeth to make replacement eye lenses! Actress Hedy Lamarr's frequency-hopping spread-spectrum invention! The early days of Jim Jones! Asteroid-hunting space telescopes!

  • Chive Ep39 - Samm Levine

    · Chive Podcast

    Actor Samm Levine has a pretty cool gig co-hosting Kevin Pollak's Chat Show, and you'll hear about that. But you'll also hear just how intense director Quentin Tarantino was on the set of "Inglorious Bastards," and what it was like learning comedy from Judd Apatow and the incredible cast of TV's "Freaks & Geeks." Plus, Samm drops quite a revelation about actor/comedian Dave Coulier (yes, the guy from "Full House").

  • PMC 69: Pop My Oscars! Myq Kaplan and Samm Levine

    · Pop My Culture Podcast

    Myq Kaplan ("Last Comic Standing") and Samm Levine ("Freaks & Geeks") join Cole and Vanessa for an hour of straight-up Academy Awards talk! The four get Extremely Loud & Incredibly close as they make their predictions of who will and should win those gold statuettes, try to make sense of Tree of Life, argue about Hugo, mention Drive a lot, giggle at Albert Nobbs, break the silence of The Artist, and "Descendants" into madness as they give out some special awards of their own.  Let us know your special Oscar award (any sort of recognition you'd like to give to something from film this year that wasn't nominated) on our website for a chance to win the Entertainment Weekly Oscar issue signed by Myq, Samm, Cole and Vanessa!

  • Samm Blake

    · Way Up North

    The 8th episode of the Way Up North podcast with Australian wedding photographer Samm Blake. Samm lives and works out of Brooklyn, NY these days and besides being an amazing wedding photographer, she can also call herself a filmmaker now as her documentary about WW2 POW survivor Harold Martin is out soon. That and much more in this week's episode with Samm.

  • 00:06:21

    Xtra : The Night Before, de Jonathan Levine

    · NoCiné

    Des nouvelles du canadien Seth Rogen, dont les apparitions sur grand écran se font rares de notre côté de l’Atlantique. Preuve à l’appui : The Night Before de Jonathan Levine, un feel-good movie directement relégué à la case VOD, dégoté par notre dévoué Stéphane Moïssakis.Animé par Thomas Rozec (@thomrozec) avec Stéphane Moïssakis (@smoissakis)RÉFÉRENCES CITÉES DANS L’ÉMISSIONThe Night Before (Jonathan Levine, 2015), Warm Bodies (Jonathan Levine, 2013), Seth Rogen, Joseph Gordon-Levitt, Anthony Mackie, Tous les garçons aiment Mandy Lane (All The Boys Love Mandy Lane - Jonathan Levine, 2006), Wackness (Jonathan Levine, 2008), 50/50 (Jonathan Levine, 2010), Michael ShannonRETROUVEZ NOCINÉ PARTOUT SUR LES INTERNETS CRÉDITSEnregistré le 24 mars 2016 au Tank à Paris (11ème). Moyens techniques : Le Tank. Production : Joël Ronez - Iris Ollivault / TempsMachine.NET. Réalisation : Jules Krot. Générique : "Soupir Articulé", Abstrackt Keal Agram (Tanguy Destable et Lionel Pierres).

  • 00:36:22

    Episode 52 Interview with Gail Carson Levine and Fairy Tales

    · Beyond The Trope

    Gail Carson Levine joined us for a great discussion, and when she returned to her day, we talked about some of our favorite fair tales.   Mentioned in this episode: DAVE AT NIGHT ELLA ENCHANTED by Gail Carson Levine STOLEN MAGIC by Gail Carson Levine (April 2015) PRINCESS TEST by Gail Carson Levine FAIREST by Gail Carson Levine PRINCESS TALES Volumes 1 and 2 by Gail Carson Levine The Louisville Review Cancer Poetry Project Sugar House Review Bigger Than They Appear New York Quarterly The Newbery Honor THE TWO PRINCESSES OF BAMARRE   Fairy Tale Discussion: The Little Mermaid Hans Christian Anderson Disney Beauty and the Beast SPINDLE'S END by Robin McKinley Sleeping Beauty Cinderella Grimm Brothers Fairy Tales Hansel and Gretel Doctor Who THE LORD OF THE RINGS by J. R. R. Tolkien The Twelve Dancing Princesses ENTWINED by Heather Dixon CINDER by Marissa Meyer Rapunzel THE TAMING OF THE SHREW by William Shakespeare G. K. Chesterton C. S. Lewis

  • 00:46:25

    27: Noah Levine

    · The One You Feed - Learn Good Habits to Increase Mindfulness and Happiness and Decrease Anxiety and Depression

      This week on The One You Feed we have Noah Levine.We were lucky enough to sit down with Noah in the Against the Stream headquarters in Los Angeles. Noah's teachings are core to everything that I have come to believe over the years. I'm really excited to present this interview.Noah Levine (born 1971) is an American Buddhist teacher and the author of the books Dharma Punx: A Memoir , Against the Stream,  and The Heart of The Revolution. As a counselor known for his philosophical alignment with Buddhism and punk ideology, he founded Against the Stream Buddhist Meditation Society. As a youth, Levine was incarcerated several times. His first book, Dharma Punx, details teenage years filled with drugs, violence, and multiple suicide attempts—choices fuelled by disillusionment with American mainstream culture. His substance abuse started early in life—at age six he began smoking marijuana—and finally ended in a padded detoxification cell in juvenile prison 11 years later. It was in this cell where he hit "an emotional rock bottom" and began his Buddhist practice "out of a place of extreme drug addiction and violence".He recently started Refuge Recovery which is a community of people who are using the practices of mindfulness, compassion, forgiveness and generosity to heal the pain and suffering that addiction has caused. His new book is titled Refuge Recovery: A Buddhist Path to Recovery from Addiction.In This Interview Noah and I Discuss...The One You Feed parable.How he found Buddhism through his life failures.What "going against the stream" means.That the bad wolf has a stronger tendency in us and wins by default.How our capacity for kindness, generosity, and love have to be cultivated.Why the path of the Buddha is revolutionary.Going against the status quo.How to be in the world but not of it.The distinction between suffering and pain.The difference between craving and desire.Why suffering is not your fault.How the 1st Noble Truth normalizes the experience of suffering.The impermanent nature of all things.How we can never satisfy happiness through sense pleasure.How we layer suffering on top of our pain.Not asking "why" but instead asking "how do I respond"Meeting pain with compassion and kindness.Learning to include ourselves in our circle of compassion.The crippling power of doubt in our growth.The gradual nature of spiritual growth.How sometimes the first things we find in our spiritual practice is the bad stuff.His new program, Refuge Recovery. Noah Levine LinksAgainst the Stream homepageAgainst the Stream audio archivesNoah Levine HomepageNoah Levine Amazon Author Page Some of our most popular interviews you might also enjoy:Mike Scott of the WaterboysRich RollTodd Henry- author of Die EmptyRandy Scott Hyde

  • 00:20:19

    Circulation June 20/27, 2017 Issue

    · Circulation on the Run

    Dr. Carolyn Lam:               Welcome to Circulation on the Run your weekly podcast summary and backstage pass to the journal and it's editors. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore.                                                 Is it time to end our debates on short versus long duration of dual anti-platelet therapy? Well I will be discussing this with two very special guests in just a moment. But first here is your summary of this week's journal.                                                 The first paper tells us that HDL particle number may serve as a biomarker of residual risk when assessed on statin therapy. First author Dr. Khera, corresponding author Dr. Mora from Brigham and Women's Hospital and colleagues of the JUPITER trial assessed HDL cholesterol levels, apolipoprotein A-1, cholesterol efflux capacity and HDL particle number at baseline and 12 month in a nested case control study of the JUPITER trial. That was a randomized primary prevention trial that compared rosuvastatin to placebo in individuals with normal LDL but increased CRP levels.                                                 In the current study the authors found that cholesterol efflux capacity was moderately correlated with HDL cholesterol, apoA-I, and HDL particle number. Baseline HDL particle number was inversely associated with incident cardiovascular disease, while there was no significant association for baseline cholesterol efflux capacity, HDL or apoA-I levels. On-statin cholesterol efflux capacity was inversely associated with incident cardiovascular disease but HDL particle number again emerged as the strongest predictor.                                                 Thus for both baseline and on-statin analyses, HDL particle number was the strongest of four HDL-related biomarkers as an inverse predictor of incident events and biomarker of residual risk.  Whether therapies designed to enhance cholesterol efflux capacity or an increased HDL particle number can also reduce cardiovascular risk however remains uncertain.                                                 The next study sheds light on mechanisms underlying the de-differentiation and lineage conversion of adult human fibroblast into functional endothelial cells. First author Dr. Zhang, corresponding authors Dr. Rehman and Malik from University of Illinois College of Medicine first generated CD34+ progenitors by de-differentiating adult human skin fibroblasts and showed that these intermediate progenitors could give rise to endothelial cells as well as erythrocytes. They then showed that lineage conversion of fibroblasts via partial de-differentiation recapitulated in part the embryonic development of the vasculature as evidenced by up regulation of anti-aging enzyme telomerase and the bi-lineage potential of the generated progenitors.                                                 Importantly they showed that transcription factor SOX17 functioned as a switch which regulated the cell fate of CD34+ progenitors towards an endothelial versus erythroid lineage. Finally implanted fibroblast derived CD34+ progenitors stably engrafted to form functional human blood cells in mice that improved cardiac function after myocardial infarction. Thus the molecular switch SOX17 provides a means to optimize the generation of endothelial cells for vascular tissue regeneration or disease modeling.                                                 What do drones have to do with out of hospital cardiac arrest? Well in this next study by first author Dr. Boutilier corresponding author Dr. Chan and colleagues from University of Toronto, the authors hypothesized that a drone network designed with the aid of a mathematical model combining both optimization and queuing could reduce the time to AED arrival.                                                 Using data from over 50,000 historical out of hospital cardiac arrests covering over 26,000 square kilometers in Ontario, Canada, they found that a drone network designed to reduce the median AED arrival time by three minutes relative to the historical 911 response could also reduce the 90th percentile of the AED arrival time by between 6 minutes and 43 seconds in most urban regions and 10 minutes and 34 seconds in most rural regions.                                                 Thus this study tells us that drone delivered AEDs have the potential to be a transformative innovation in the provision of emergency care to cardiac arrest patients especially those who arrest in a private or rural setting.                                                 The next study provides thresholds for ambulatory blood pressure among African Americans. Dr. Ravenall and colleagues from New York University School of Medicine analyzed data from the Jackson Heart Study, a population-based cohort comprised exclusively of African-American adults and of whom more than 1000 participants completed ambulatory blood pressure monitoring at baseline.                                                 Based on the outcome derived approach for systolic blood pressure and a regression derived approach for diastolic blood pressure, the following definitions corresponded to clinic blood pressure of 140/90 and were proposed as ambulatory blood pressure definitions for African Americans. Daytime blood pressure above 140/85, 24 hour blood pressure above 135/80 and nighttime blood pressure above 130/75 mmHg. Note that these ambulatory blood pressure thresholds identified for African Americans were higher than those from published recommendations mainly derived in European, Asian and South American populations. The use of these ambulatory blood pressure thresholds for African Americans will lead to a lower prevalence of daytime, 24 hour and nighttime hypertension compared with the current published recommendations.                                                 The next paper provides pre-clinical evidence of a novel target in plaque information in atherosclerosis. Dr. Stachon and colleagues from Heart Center Friburg University in Germany hypothesized a functional role of the signal axis ATP binding to purinogenic receptor P2X7 in inflammasone activation and chronic inflammation driving atherosclerosis.                                                 In an elegant series of experiments they showed that P2X7 receptor activation was crucial for inflammasone assembly and interleukin-1-beta secretion. The lack of P2X7 in mice abolished inflammasone activation in atherosclerotic lesions. P2X7 was expressed in murine and human atherosclerotic lesions. LDL receptor deficient mice lacking P2X7 receptor had reduced plaque inflammation and were less prone to develop atherosclerosis.                                                 Thus this study shows that P2X7 inhibition could be a treatment strategy against plaque inflammation in atherosclerosis.                                                 The next paper describes the first prospective clinical study of adenosine use in pediatric and young adult patients after heart transplantation. Now prior to this study adenosine was relatively contraindicated post-transplant due to a presumed risk of prolonged atrioventricular block in denervated hearts.                                                 In the current study first author Dr. Flyer corresponding author Dr. Silver and colleagues from Columbia University performed a single center prospective clinical study testing whether adenosine caused prolonged asystole after transplant and if it was effective in blocking AV nodal conduction in healthy heart transplant recipients aged 6 months to 25 years presenting for routine cardiac catheterization. Following catheterization, a transvenous pacing catheter was placed and adenosine was given following a dose escalation protocol until AV block was achieved.                                                 Eighty patients completed adenosine testing. And no patient required rescue ventricular pacing. AV block was observed in 77 patients with the median longest AV block of 1.9 seconds and the mean duration of adenosine effect of 4.3 seconds.                                                 Thus, this study suggests that adenosine may be safe and effective in patients post transplantation and establishes both a safe and effective starting dose of 25mcg/kg or 1.5mg for patients weighing 60kg and more. It also establishes a stepwise therapy escalation plan to avoid prolonged bradycardia. Although patients after heart transplantation may require less adenosine to achieve AV block it appears to be safe and effective as therapy for evaluation and or treatment of tachycardia in this population.                                                 Well those were your summaries, now for our feature discussion.                                                 Today for our feature discussion we are talking about a very familiar situation, dual anti-platelet therapy following coronary intervention and the decision of long versus short duration of therapy. A debate we've heard many times but according to the perspective piece in today's journal, maybe a debate we should end. And I am so pleased to have the author, Dr. Glenn Levine from Baylor College of Medicine as well Dr. Laura Mauri associate editor from Brigham and Women's Hospital.                                                 Welcome both. Dr. Laura Mauri:               Thank you Carolyn. Dr. Glenn Levine:             Thank you. Dr. Carolyn Lam:               Glenn would you like to start by presenting your case. It's time to end a dualistic short versus long duration of DAPT debate. I really like that title, tell us more. Dr. Glenn Levine:             Thank you Carolyn.                                                 The point we make in our editorial is that over the last five or six years there have been studies comparing what I term standard, which is usually about 12 months DAPT versus shorter duration DAPT and there are other studies comparing standard DAPT versus longer duration DAPT. Those generated important information in different people interpret them in different ways. What though has happened over the last several years is certainly for both educational and entertainment value at meetings as well in editorials, the idea of how long people should be treated with DAPT has been oversimplified to whether all patients should be treated with short duration or long duration. And Laura herself knows that as she has been in many of these debates.                                                 While I think that initially that was educational and entertaining, I think these days people understand those points and a greater issue is in that we should treat some people with short duration, some with what I call standard and some with long duration. And rather than debating whether everyone should treated with short or everyone should be treated with long, I think what we need to focus on now is which patients should be treated with short duration, which are probably best treated with a standard duration and which are best treated with prolonged or extended duration DAPT.                                                 And that in a nutshell is the main point that we make in this perspective editorial. Dr. Carolyn Lam:               Laura, so do you agree? Dr. Laura Mauri:               I couldn't agree more. I think clinicians really are looking for guidance and what happens at these debates is you see these polarizing opinions that debaters are asked to defend when in actuality there's such a wide spectrum of what individual patients need. And the real question I think going forward is how to end these debates and how to provide really more tailored information so clinicians and patients can make better decisions together. And I think that's really where the piece that Glenn has written really helps direct us. Dr. Carolyn Lam:               Yeah, Glenn, I mean are we talking about the usual risk versus benefits and precision metsan or individualized risk assessment here? Dr. Glenn Levine:             Yeah, what we're talking about is looking at the ischemic risks which are primarily leg stent thrombosis or spontaneous MI versus the bleeding risks which is obviously bleeding and balancing them. And there clearly are decision tools available to clinicians. Laura has pioneered the DAPT score which is an incredibly user friendly and easy tool to use to assess which patients should be continued with prolonged DAPT or not. And there are also some other tools out there including the Paris registry score perhaps a little more complex and then there's also now the precise DAPT score which one can at least assess bleeding risk and indirectly assess the ischemic and bleeding risk.                                                 But really I think that is the focus now on balancing bleeding and ischemic risks and having pools to allow clinicians to easily do that. Dr. Carolyn Lam:               That's true. Now do you think guidelines have to catch up or have they caught up? Dr. Glenn Levine:             Our DAPT duration guideline was coming out just as Laura's DAPT score was about to be published, several months after it had been presented. And we did mention the DAPT score in our paper, it was too early to formally incorporate it into the guidelines. Nevertheless, the way our guidelines are written, they clearly give practitioners the option for individualizing therapy based on ischemic and bleeding risk and Laura's DAPT score fits perfectly into what we aim to do, namely to encourage practitioners to assess patients on an individual level and assess what duration of DAPT is best. Dr. Carolyn Lam:               I do have a question for Laura here though. I see Asian patients, I'm talking to you here from Singapore. And sometimes you wonder the trial situations and what you derive there. How does it differ from real world and how is it impacting your practice for example Laura? Dr. Laura Mauri:               That's a great question. I think you have a number of points there. One is the generalized ability or results from one trial across the world where you might have many different patient populations. And while the DAPT score was an international trial it would be interesting to see more data coming out from other different countries. And as you know there are trials in Asia that have looked at randomized DAPT duration as well.                                                 I think now that we have better access to information especially in cardiology globally, we can get that information and better tailor therapy. When we look at any one randomized trial the results might seem kind of black and white and to certain extent so do guideline recommendations but we are getting better at using the results from randomized trials to really identify risk factors. I think that with time we'll be able to either validate the DAPT score in other patient populations or develop tailored scores from unique data sets. I think the challenge really is making sure that we still get good randomized evidence for our treatment decisions but then when we have treatments that have both benefit and risk that we identify which sub-populations of patients really do achieve most of the benefit. And then the other populations that might be harmed. And that's really what we try to do with this score.                                                 And I think what you'll see, you asked about precision medicine which usually we think about using genetics but I think there's so much just really basic information that we have about patient lesion characteristics and other specific factors that we record routinely in their medical records that we can use and you'll see this, I think more and more frequently across different areas of investigation and in cardiovascular medicine.                                                 One really interesting example recently was this French trial. Data was used to be able to predict, very similar to what we did, but to predict which patients would benefit from lower blood pressure without the risk of more aggressive treatment. Dr. Carolyn Lam:               Yeah, I love the way you put that. Those are really words of wisdom, I do think that that is the way cardiovascular medicine is gonna move. Glenn, how do you put all this into practice for yourself? Dr. Glenn Levine:             I think whether or not I formally calculate a DAPT score or Paris registry score, I think clearly we integrate the factors in those scores into our everyday practice. And clearly there are patients who are at high bleeding and low ischemic risk and vice versa. I would also encourage listeners to in addition to all the scores, one has to think about the consequences of a recurrent MI or stent thrombosis. Obviously someone who has stent thrombosis of a proximal LED lesion, if they already have a depressed EF or occluded RCA, those consequences are likely much more dire then someone who occludes say at a distal OM3 stent who has the normal ejection fraction. It also encourages them to think about the consequences of stent thrombosis as well as the consequences of a recurring MI. Dr. Laura Mauri:               Just to make it clear, we know that clinicians have always tried to balance these different risks of ischemia and bleeding when faced with this decisions. I think the challenge really has been the limited amount of information that we've had to be able to do that. And so we've really just used kind of our gut until recently when we've had several large randomized data sets to be able to look to. And what that's done is it's given us the ability to construct these new tools to be able to make practice more data driven. Now still individualized but based on data that's tailored to our patients.                                                 And so I think we can use that to be able to improve outcomes. That being said, we don't want to rely on a statistic or a score alone and things like the DAPT score are based on patients like the ones that were enrolled into the randomized trial. Those were patients who could take longer anti-platelet therapy. It helps to identify who can take it for longer. But there are patients who get anti-coagulation or have other serious bleeding risks who really are going to benefit from new technologies to be able to shorten anti-platelet therapy. Dr. Carolyn Lam:               Well thank you Glenn once again for a wonderful perspective piece that has really got us thinking about situations even beyond dual anti-platelet therapy. Thank you Laura for your insights and thank you listeners for joining us today. Join us again next week.

  • 02:20:00

    Seth Herzog, Samm Levine, Greg Wyshynski and 9 others guest

    · Doug Loves Movies

    Live from the Gramercy Theatre in New York City, Doug ushers in the second 12 Guests of Christmas episode of the season with Desmin Borges, Rich Dimirinis, Luis J. Gomez, Josh Gondelman, Seth Herzog, Ian Kinney, Samm Levine, Julia Mattison, Sam Pasternack, George Salazar, Tom Thakkar and Greg Wyshynski.

  • 02:21:45

    Schmoedown Rundown #60: The Immortal Samm Levine

    · The Schmoes Know Show

    On Schmoedown Rundown #60, Aaron Turner, Frank Janisch and Brian Davids discuss the finals of the Ultimate Schmoedown Team and Singles Tournaments including Samm Levine vs. JTE and Above The Line vs. Team Action. The episode concludes with a major announcement. Every Saturday on The Schmoedown Rundown, Aaron Turner (@attitanium), Frank Janisch (@FrankieJ29) and Brian Davids (@BDF331) discuss the ins and outs of the Movie Trivia Schmoedown including the latest matches, league news and upcoming matches. Follow @SDRundown for the latest show news, guest announcements and giveaways as well as @SDRundownStats for the latest Schmoedown stats.Creative Direction/Artwork by Bryan Ward (@BryanEWard).Subscribe/Rate/Review on iTunes: to Schmoes Know on Youtube: to Collider Video on YouTube: PLUS SCHEDULE:DON'T BE A BEARDO: & SOUND: TOP 10 SHOW: MEANING OF: WANGER SHOW: NATION: SCHMOE:

  • 01:10:38

    Gilbert Gottfried, Neil Berkeley, Joe DeRosa and Samm Levine guest

    · Doug Loves Movies

    Live from the Millennium Biltmore Hotel in Los Angeles, Doug welcomes Gilbert Gottfried, Neil Berkeley, Joe DeRosa and Samm Levine to a special LA Podfest edition of the show.

  • 03:54:06

    Schmoedown Rundown #50 with Samm Levine

    · The Schmoes Know Show

    On Schmoedown Rundown #50, Aaron Turner, Frank Janisch and Brian Davids welcome Samm Levine to the show for an in-depth interview regarding Above The Lines Ultimate Schmoedown Tournament success as well as Samms Schmoedown career to date. The guys also recap the singles titles match between Dan Murrell and Kristian Harloff as well as Above The Line vs. Wolves of Steel; The Maltin Falcons vs. Cinema Sins and Team Action vs. Top 10.Every Saturday on The Schmoedown Rundown, Aaron Turner (@attitanium), Frank Janisch (@FrankieJ29) and Brian Davids (@BDF331) discuss the ins and outs of the Movie Trivia Schmoedown including the latest matches, league news and upcoming matches. Follow @SDRundown for the latest show news, guest announcements and giveaways as well as @SDRundownStats for the latest Schmoedown stats.Creative Direction/Artwork by Bryan Ward (@BryanEWard).Subscribe/Rate/Review on iTunes: to SK Podcast on YouTube: to Schmoes Know on Youtube: to Collider Video on YouTube: to Collider Video on iTunes